BEAM
Beam Therapeutics
NASDAQ: BEAM · Cambridge, MA · Healthcare
$24.05-0.51 (-2.08%)Closed
Market Cap$2.84B
Cash$978.0Mmost recent
Runway30 mo$98.0M Q burn
P/E (TTM)—EPS $-4.65
52-Wk Range$20.60 – $37.92
Avg Volume2.0M3-month
Healthstable
Base-editing company developing precision genetic medicines for sickle cell disease, oncology, and inherited metabolic disorders.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
Pipeline
Drug candidates sponsored by BEAM · ClinicalTrials.gov
Couldn't load pipeline. ClinicalTrials.gov or the backend may be unavailable.
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.